IP Library Granted Patent US 12,279,958
Granted Patent B2
US 12,279,958 · App. 18/302,669 · Granted Apr 22, 2025

Interbody spacer for spinal fusion

Inventor: Josh Arnone (St. Charles, MO)
Assignee: CORELINK, LLC
A61F2/30767A61F2/30771A61F2/30907A61F2/4455A61F2/4465A61F2/447A61F2002/2835A61F2002/30011A61F2002/30774A61F2002/30904A61F2002/3092A61F2002/3093A61F2002/30968A61F2002/30978A61F2002/30985A61F2002/4629
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,279,958
App. No.
18/302,669
Granted
Apr 22, 2025
Kind
B2
Abstract

An interbody spacer for spinal fusion surgery includes first and second opposite side walls that have open-cell metal foam at upper and lower faces, and a three-dimensional lattice disposed between open-cell metal foam at the upper and lower faces. The open-cell metal foam is in communication with the three-dimensional lattice so that bone growth can enter the three-dimensional lattice from the open-cell metal foam. The interbody spacer may be formed by additive manufacturing.

Claims (34)

1. An interbody spacer for spinal fusion surgery, the interbody spacer comprising:

first and second opposite longitudinal end portions, wherein a longitudinal axis of the interbody spacer extends through the first and second opposite end portions;

first and second opposite side walls extending longitudinally between and interconnecting the first and second longitudinal end portions, wherein the first and second opposite side walls define a width of the interbody spacer therebetween, the first and second opposite side walls having interior and exterior surfaces;

upper and lower faces at respective upper and lower portions of the corresponding first and second opposite longitudinal end portions and first and second opposite side walls, wherein the upper and lower faces define a height of the interbody spacer therebetween; and

an interior cavity defined by the first and second opposite longitudinal end portions and the interior surfaces of the first and second opposite side walls, wherein the interior cavity extends through the upper and lower faces,

wherein each of the first and second opposite side walls includes

open-cell metal foam at the upper and lower faces, and

teeth at the upper and lower faces adjacent outer perimeters of the upper and lower faces.

2. The interbody spacer set forth in claim 1 , wherein each of the first and second opposite side walls includes a three-dimensional lattice disposed between the open-cell metal foam at the upper and lower faces, wherein the open-cell metal foam is in communication with the three-dimensional lattice so that bone growth can enter the three-dimensional lattice from the open-cell metal foam, wherein the three-dimensional lattice of each of the first and second opposite side walls defines a set of transverse passages extending transversely through the corresponding side wall from the interior cavity through the exterior surface of the side wall, a set of heightwise passages extending heightwise through the three-dimensional lattice from an upper end of the three-dimensional lattice to a lower end of the three-dimensional lattice, and a set of longitudinal passages extending generally longitudinally through the three-dimensional lattice from a first longitudinal end to a second longitudinal end of the three-dimensional lattice.

3. The interbody spacer set forth in claim 2 , wherein the transverse passages, the heightwise passages, and the longitudinal passages intersect and are in communication with one another.

4. The interbody spacer set forth in claim 2 , wherein an open area of each three-dimensional lattice increases from adjacent the exterior surface of the corresponding side wall toward the interior surface of the corresponding side wall.

5. The interbody spacer set forth in claim 4 , wherein a structural integrity of each three-dimensional lattice increases from adjacent the exterior surface of the corresponding side wall toward the interior surface of the corresponding side wall.

6. The interbody spacer set forth in claim 2 , wherein the transverse passages are arranged in longitudinal and heightwise rows extending longitudinally and heightwise of the corresponding side wall.

7. The interbody spacer set forth in claim 6 , wherein a cross-sectional area of each transverse passage gradually increases from the exterior surface to the interior surface of the corresponding side wall.

8. The interbody spacer set forth in claim 2 , wherein the heightwise passages are arranged in rows extending longitudinally and transversely along the corresponding side wall.

9. The interbody spacer set forth in claim 8 , wherein a cross-sectional area of each heightwise passage generally increases from adjacent the exterior surface toward the interior surface of the corresponding side wall.

10. The interbody spacer set forth in claim 2 , wherein the longitudinal passages are arranged in rows extending heightwise and transversely along the corresponding side wall.

11. The interbody spacer set forth in claim 10 , a cross-sectional area of each longitudinal passage generally increases from adjacent the exterior surface toward the interior surface of the corresponding side wall.

12. The interbody spacer set forth in claim 1 , wherein the interbody spacer is an integrally formed, one-piece component formed by additive manufacturing.

13. A method of forming an interbody spacer comprising:

forming the interbody spacer as an integral, one-piece interbody spacer by additive manufacturing process, wherein the formed integral, one-piece interbody spacer comprises:

first and second opposite longitudinal end portions, wherein a longitudinal axis of the interbody spacer extends through the first and second opposite end portions;

first and second opposite side walls extending longitudinally between and interconnecting the first and second longitudinal end portions, wherein the first and second opposite side walls define a width of the interbody spacer therebetween, the first and second opposite side walls having interior and exterior surfaces;

upper and lower faces at respective upper and lower portions of the corresponding first and second opposite longitudinal end portions and first and second opposite side walls, wherein the upper and lower faces define a height of the interbody spacer therebetween; and

an interior cavity defined by the first and second opposite longitudinal end portions and the interior surfaces of the first and second opposite side walls, wherein the interior cavity extends through the upper and lower faces,

wherein each of the first and second opposite side walls includes

open-cell metal foam at the upper and lower faces, and

teeth at the upper and lower faces adjacent outer perimeters of the upper and lower faces.

14. The interbody spacer set forth in claim 1 , wherein the open-cell metal foam is disposed inward of the teeth at the upper and lower faces relative to the outer perimeters of the upper and lower faces.

15. The interbody spacer set forth in claim 14 , wherein the open-cell metal foam is recessed relative to the teeth.

16. The interbody spacer set forth in claim 1 , wherein the open-cell metal foam is recessed relative to the teeth.

17. The method of forming an interbody spacer set forth in claim 13 , wherein the open-cell metal foam is disposed inward of the teeth at the upper and lower faces relative to the outer perimeters of the upper and lower faces.

18. The method of forming an interbody spacer set forth in claim 17 , wherein the open-cell metal foam is recessed relative to the teeth.

19. The method of forming an interbody spacer set forth in claim 13 , wherein the open-cell metal foam is recessed relative to the teeth.

Assignments (3)
SECURITY INTEREST Recorded Jul 22, 2024
From: CORELINK, LLC
To: VARAGON CAPITAL PARTNERS AGENT, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 068045/0638 →
SECURITY INTEREST Recorded Jun 24, 2024
From: CORELINK, LLC
To: VARAGON CAPITAL PARTNERS AGENT, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 067820/0916 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2023
From: ARNONE, JOSH
To: CORELINK, LLC
Reel/Frame 063366/0972 →
Continuity (6)
Continuation 17951787 · Sep 23, 2022
Continuation 17664150 · May 19, 2022
Continuation 16722090 · Dec 20, 2019
Continuation 15792140 · Oct 24, 2017
Provisional Application 62412091 · Oct 24, 2016
Related Publication 20230248526A1 · Aug 10, 2023
References Cited (50)
US 4834757A · Brantigan · 1989 [cited by applicant]
US 4863476A · Shepperd · 1989 [cited by applicant]
US 5171278A · Pisharodi · 1992 [cited by applicant]
US 5282861A · Kaplan · 1994 [cited by applicant]
US 5702449A · McKay · 1997 [cited by applicant]
US 9782270B2 · Wickham · 2017 [cited by applicant]
US 10271958B2 · Schaufler et al. · 2019 [cited by applicant]
US 10512545B2 · Arnone · 2019 [cited by examiner]
US 10675158B2 · Unger et al. · 2020 [cited by applicant]
US 20030009227A1 · Lambrecht · 2003 [cited by examiner]
US 20030040802A1 · Errico · 2003 [cited by examiner]
US 20030065396A1 · Michelson · 2003 [cited by examiner]
US 20030105527A1 · Bresina · 2003 [cited by examiner]
US 20030109933A1 · Weissman · 2003 [cited by examiner]
US 20030135276A1 · Eckman · 2003 [cited by examiner]
US 20030153985A1 · Lee · 2003 [cited by examiner]
US 20030158553A1 · Michelson · 2003 [cited by examiner]
US 20040019386A1 · Ferree · 2004 [cited by examiner]
US 20040034351A1 · Sherman · 2004 [cited by examiner]
US 20040059418A1 · Mckay · 2004 [cited by examiner]
US 20050112397A1 · Rolfe · 2005 [cited by examiner]
US 20060241765A1 · Burn · 2006 [cited by examiner]
US 20060241776A1 · Brown · 2006 [cited by examiner]
US 20070118229A1 · Bergin · 2007 [cited by examiner]
US 20070198021A1 · Wales · 2007 [cited by examiner]
US 20070219634A1 · Greenhalgh · 2007 [cited by examiner]
US 20080077247A1 · Murillo · 2008 [cited by examiner]
US 20080124766A1 · Kuboki · 2008 [cited by examiner]
US 20090048675A1 · Bhatnagar et al. · 2009 [cited by applicant]
US 20100198353A1 · Pope · 2010 [cited by examiner]
US 20110125284A1 · Gabbrielli · 2011 [cited by examiner]
US 20120316650A1 · Ullrich, Jr. · 2012 [cited by examiner]
US 20130030529A1 · Hunt · 2013 [cited by examiner]
US 20140107786A1 · Geisler · 2014 [cited by examiner]
US 20150018956A1 · Steinmann · 2015 [cited by examiner]
US 20160158023A1 · Klimek · 2016 [cited by examiner]
US 20170173225A1 · Troxel · 2017 [cited by examiner]
US 20170266007A1 · Gelaude · 2017 [cited by examiner]
US 20180110624A1 · Arnone · 2018 [cited by applicant]
US 20180289496A1 · Zappacosta · 2018 [cited by examiner]
US 20180338838A1 · Cryder · 2018 [cited by examiner]
US 20190038428A1 · Stauffer · 2019 [cited by examiner]
US 20190053907A1 · Gregersen · 2019 [cited by examiner]
US 20190083270A1 · Milz · 2019 [cited by examiner]
US 20190142601A1 · Ashleigh · 2019 [cited by examiner]
US 20190175354A1 · Knox · 2019 [cited by examiner]
US 20190224023A1 · Howard · 2019 [cited by examiner]
CN 105559950A · 2016 [cited by applicant]
WO 2017191223A1 · 2017 [cited by applicant]
Notice of Allowance from U.S. Appl. No. 17/664,150, dated May 23, 2024, 10 pages. [cited by applicant]